A 14-year study on 202,000 women, published in the Lancet, has demonstrated how an algorithm can refine CA125 test data to achieve a diagnostic decision on the risk of ovarian cancer. This study is a landmark achievement in the prognosis of an apparently unpredictable carcinogenic event. Ovarian cancer is the seventh most common cancer in women worldwide with around 240,000 cases each year. There is no standard or routine screening test for ovarian, fallopian tube, and primary peritoneal cancer. The mortality rate is high due to such pure prognosis.
A blood test, called CA125, can pick up signs of tumors in the ovaries, but it’s not very specific or sensitive for these growths. CA125 levels can rise not just because of ovarian tumors but during menstruation and pregnancy as well. That may explain why the test only picks up 60% to 65% of cancers. In this study scientists claimed to…
